Page last updated: 2024-11-07

kw 2189

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

KW 2189: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132979
CHEMBL ID36015
SCHEMBL ID14499178
MeSH IDM0230329

Synonyms (14)

Synonym
unii-ihk933kcic
pibrozelesin [inn]
methyl (s)-8-(bromomethyl)-3,6,7,8-tetrahydro-4-hydroxy-2-methyl-6-((5,6,7-trimethoxyindol-2-yl)carbonyl)benzo(1,2-b:4,3-b')dipyrrole-1-carboxylate, 4-methyl-1-piperazinecarboxylate (ester)
benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methyl-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (s)-
154889-68-6
methyl(1s)-1-bromomethyl-7-methyl-5-((4-methylpiperazinyl)carbonyloxy)-3-((5,6,7-trimethoxy-2-indolyl)carbonyl)-1,2-dihydro-3h-pyrrolo(3,2-e)indole-8-carboxylate hydrobromide
ihk933kcic ,
kw 2189
CHEMBL36015
pibrozelesin
methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate
pibrozelesin [who-dd]
SCHEMBL14499178
Q27280739
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID122181In vivo concentration required to inhibit the colon 26 murine adrenocarcinoma cell growth by 50%1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID122160In vivo antitumor activity (0.707 mg/Kg) is the measure of tumor growth inhibition of colon 26 murine adrenocarcinoma cells.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID231736Ratio between max dose within 10% body weight loss and tumor growth inhibition1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID122166In vivo antitumor activity (1 mg/kg) is the measure of tumor growth inhibition of human tumor xenograft DLD-1 (colon) implanted sc in mice.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID87613Concentration required to inhibit the growth of HeLaS3 human uterine cervix carcinoma cells by 50%1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID122167In vivo antitumor activity (1 mg/kg) is the measure of tumor growth inhibition of human tumor xenograft HCT116 (colon) implanted sc in mice.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID122168In vivo antitumor activity (1 mg/kg) is the measure of tumor growth inhibition of human tumor xenograft WiDr (colon) implanted sc in mice.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
AID122161In vivo antitumor activity (0.716 mg/kg) is the measure of tumor growth inhibition of human tumor xenograft NUGC-3 (stomach) implanted sc in mice.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (60.00)18.2507
2000's4 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (40.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]